595 related articles for article (PubMed ID: 16510575)
1. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
[TBL] [Abstract][Full Text] [Related]
3. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
7. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
8. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
9. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
10. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
Ma W; Tessarollo L; Hong SB; Baba M; Southon E; Back TC; Spence S; Lobe CG; Sharma N; Maher GW; Pack S; Vortmeyer AO; Guo C; Zbar B; Schmidt LS
Cancer Res; 2003 Sep; 63(17):5320-8. PubMed ID: 14500363
[TBL] [Abstract][Full Text] [Related]
11. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model.
Bader HL; Hsu T
BMC Cancer; 2016 Oct; 16(1):797. PubMed ID: 27733136
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo.
Rankin EB; Biju MP; Liu Q; Unger TL; Rha J; Johnson RS; Simon MC; Keith B; Haase VH
J Clin Invest; 2007 Apr; 117(4):1068-77. PubMed ID: 17404621
[TBL] [Abstract][Full Text] [Related]
15. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.
Schietke RE; Hackenbeck T; Tran M; Günther R; Klanke B; Warnecke CL; Knaup KX; Shukla D; Rosenberger C; Koesters R; Bachmann S; Betz P; Schley G; Schödel J; Willam C; Winkler T; Amann K; Eckardt KU; Maxwell P; Wiesener MS
PLoS One; 2012; 7(1):e31034. PubMed ID: 22299048
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
17. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
18. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
19. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
20. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
